Experimental HIV vaccine trimer 4571 tested in small safety trial
NCT ID NCT04985760
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tested an experimental HIV vaccine called Trimer 4571 in 32 adults with HIV who were already on effective antiretroviral therapy (ART). The main goal was to check if the vaccine is safe and tolerable, and to see if it helps the immune system produce broadly neutralizing antibodies against HIV. Participants received either a low dose, high dose, or placebo vaccine, and were monitored for side effects and immune responses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trimer 4571 HIV vaccine with alum adjuvant
What this could lead to
If successful, this could help develop a vaccine that trains the immune system to produce broadly neutralizing antibodies against HIV, potentially leading to better HIV control or prevention strategies.
What could go wrong
This is a very early Phase 1 trial with only 32 participants, so results may not apply broadly. The vaccine is still experimental and may not produce the desired immune response or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AIDS Clinical Trials Unit/The Ohio State University
Columbus, Ohio, 43210, United States
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States